Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions
CNS Specialist ‘Now Able To Bring New Products To The Greek Market’
Executive Summary
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
You may also be interested in...
Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile
Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
Neuraxpharm’s New Belgian Division Advances European Expansion Strategy
Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established.
Neuraxpharm Expands European Reach With Dutch Operation
Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.